David Brister

Bio

David assists with new investments and contributes to the development of portfolio companies with a focus on healthcare and life sciences. David has over 20 years experience in both private equity and in operational roles and was instrumental in the successful development of venture capital businesses at 3i and MVM. During that time he was responsible for many successful investments and exits including Cambridge Antibody Technology (listed in 1997 and acquired by AstraZeneca for £702m), Acambis (listed in 1995 and acquired by Sanofi Pasteur for £276m) and Oxford GlycoSciences (listed in 1998 and acquired by Celltech for £102m) and was chairman of Domantis (acquired by GlaxoSmithKline for £230m). More recently he was Chief Business Officer and a member of the executive management team that transformed Evotec (listed on NASDAQ and the Frankfurt Stock Exchange) through a series of M&A transactions. David is currently Chairman or Non-Executive Director of several high growth life science and technology companies. David holds a BSc in Genetics & Zoology from Sheffield University. Currently Chairman or Non-Executive Director of several high growth life science and technology companies.